Additionally, the reduction of visceral and ectopic adipose tissue, resulting from the treatment with SGLT2i in patients with T2DM, leads to improved insulin sensitivity, whereas the same treatment reduces, in quantity, the plasmatic levels of triglycerides and total cholesterol, with beneficial qualitative changes on the LDL and HDL particles [34,77,78]. This evidence concerns the gene INS and type 2 diabetes mellitus.